Time filter

Source Type

Li F.,Tongji University | Sun J.,Tongji University | Zhu H.,Huangpu District Central Hospital | Wen X.,Tongji University | And 2 more authors.
Colloids and Surfaces B: Biointerfaces | Year: 2011

The poly(lactide-co-glycolide)-coated magnetic nanoparticles (PLGA MNPs) were prepared as carriers of doxorubicin (PLGA-DOX MNPs) through water-in-oil-in-water (W/O/W) emulsification method. The characteristics of PLGA-DOX MNPs were measured by using transmission electron microscopy (TEM) and vibrating-sampling magnetometry (VSM). It was found that the synthesized nanoparticles were spherical in shape with an average size of 100 ± 20. nm, low aggregation and good magnetic responsivity. Meanwhile, the drug content and encapsulation efficiency of nanoparticles can be achieved by varying the feed weight ratios of PLGA and DOX particles. These PLGA-DOX MNPs also demonstrated sustained release of DOX at 37 °C in buffer solution. Besides, influence of drug-loaded nanoparticles on in vitro cytotoxicity was determined by MTT assay, while cellular apoptosis was detected by Annexin V-FITC apoptosis detection kit. The results showed that PLGA-DOX MNPs retained significant antitumor activities. Therefore, PLGA-DOX MNPs might be considered a promising drug delivery system for cancer chemotherapy. © 2011 Elsevier B.V. Source

Li F.,Tongji University | Guo Y.,Tongji University | Han L.,Tongji University | Duan Y.,Tongji University | And 7 more authors.
Oncology Letters | Year: 2012

Retroviruses encoding the TNF-related apoptosis-inducing ligand (TRAIL) gene were generated by transient transfection of the retrovirus packing cell line BOSC 23 using TRAIL-encoding plasmid. The retrovirus was able to transduce drug-resistant A2780/DDP ovarian carcinoma cells in vitro and induce TRAIL expression in the cells, as detected by western blot assay. Furthermore, the TRAIL protein led to the growth inhibition of the cells via a caspase-activated apoptotic mechanism. It was confirmed that exposure of such cells to cisplatin in combination with the TRAIL-encoding retrovirus resulted in higher anticancer activity in vitro and in the xenograft A2780/DDP tumor in a nude mouse model. This study suggests that chemotherapy in combination with TRAIL gene therapy may be an efficient approach to treat drug-resistant ovarian cancer. Source

Zhang S.-K.,Huangpu District Central Hospital | Chen G.,Huangpu District Central Hospital
Journal of Shanghai Jiaotong University (Medical Science) | Year: 2015

Objective: To prospectively observe the incidence of radiation dermatitis (RD) on the chest wall of patients underwent postmastectomy radiotherapy (PMRT) and analyze risk factors relevant to the incidence of RD. Methods: The prospective cohort analysis was performed for 786 female patients with stage II-III breast cancer who underwent PMRT. The skin of chest wall was observed and assessed weekly from the beginning of PMRT. The primary endpoint was 90 days after PMRT and the secondary endpoint was the incidence of Grade 1-3 RD symptoms defined by CTCAE v4.03. Results: The accumulative incidence of RD within 90 d after PMRT was 30.2% (n=237) and 184 of them developed RD during PMRT and 53 of them developed RD after PMRT. Multivariate analysis indicated that diabetes, obesity, and the use of skin bolus were correlated with the incidence of RD. Conclusion: Diabetes, obesity, and the use of skin bolus are risk factors of RD on the chest wall of patients underwent PMRT. Especially diabetes and the use of skin bolus significantly correlate with the incidence of grade 2-3 RD. Evaluation of relevant risk factors and carefully considering about the use of skin bolus before determining the radiotherapy plan are helpful for reducing the risk of developing RD of patients underwent PMRT. ©, 2015, Editorial Department of Journal of Shanghai Second Medical University. All right reserved. Source

Jiang K.,Shanghai University of Traditional Chinese Medicine | Xue X.-H.,Shanghai University of Traditional Chinese Medicine | Li W.,Huangpu District Central Hospital
Tumor | Year: 2013

Objective: To investigate the diagnostic methods and clinicopathological features of patients with DCIS (ductal carcinoma in situ ) and DCIS-MI (DCIS with microinvasion), and to provide the clinical evidence for early diagnosis and treatment selection. Methods: The clinical records of 182 patients with DCIS and DCIS-MI between March 2007 and October 2010 were retrospectively reviewed. The information of CBE (clinical breast examination), imaging findings and pathology were collected. The follow-up was performed after operation. Results: In 182 patients, 97 of whom were DCIS and 85 were DCIS-MI, accounting for 14.56% of total patients with breast cancer (n = 1 250) recruited in our hospitals during the same period. Among them, 67 (36.81%) had palpable breast lesion and 115 (63.19%) had non-palpable breast lesion. Among 67 cases of non-palpable breast lesion, 49 were detectable through both of diagnostic mammography and ultrasound examination. Among 115 cases of non-palpable breast lesion, 23 were only detectable through ultrasound examination, 40 through mammography, 2 through MRI (magnetic resonance imaging), and 31 through both mammography and ultrasound examination. Nineteen cases of simple nipple discharge were diagnosed through fiberoptic ductoscopy. Among 182 cases, 111 patients had breast cancer smaller than or equal to 2 cm, 71 patients had breast cancer larger than 2 cm. The proportions of breast cancer larger than 2 cm were 36.62% (26/97) and 63.38% (45/85) in DCIS patients and DCIS-IM patients, respectively (P = 0.000 3). ER (estrogen receptor)/PR (progesterone receptor)-positive rate was significantly higher in DCIS patients than that in DCIS-MI patients (71.13% vs 55.29%, P = 0.01), while there was no significant difference in HER-2 (human epidermal growth factor receptor-2) overexpression rate (P = 0.12). The proportion of patients with Ki-67 14% was significantly less in DCIS patients than that in DCIS-MI patients (P = 0.02). All the patients were followed-up for 15 to 57 months, and only one patinet had died due to cerebrovascular accident, and the remaining 181 patinet had no recurrence or metastasis. Conclusion: Mammography combined with ultrasound examination is the most important imaging methods for early diagnosis of breast cancer. The prognostic predictors for DCIS or DCIS-MI based on the clinical and pathological measurements may facilitate the treatment decision. Copyright © 2013 by TUMOR. Source

Li F.,Tongji University | Niu S.,Tongji University | Sun J.,Tongji University | Zhu H.,Huangpu District Central Hospital | And 4 more authors.
Journal of Nanomaterials | Year: 2011

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) presents great promise as an anticancer agent for human cancer therapy. In this study, a magnetofection agent (polyMAG-l000) was evaluated for in vitro delivery of TRAIL gene towards drug-resistant A2780/DDP ovarian cancer cells. Transfection experiments showed that polyMAG-l000 was able to transfect A2780/DDP cells in vitro, leading to a higher level of TRAIL gene expression in the presence of a static magnetic field as compared to other transfection agent, such as Lipofectamine 2000. TRAIL gene expression in the A2780/DDP cells was also confirmed by Western blot analysis. Moreover, the TRAIL gene expression exhibited remarkable decrease in the cell viability, as determined by MTT assay. Importantly, PolyMAG-l000-mediated TRAIL gene transfection in the presence of anticancer drug cisplatin (CDDP) induced much higher percentages of apoptotic A2780/DDP cells, compared to TRAIL gene transfection or CDDP treatment alone. A further study by Western blot analysis indicated that cytochrome c release and caspase-9 cleavage pathway were associated with the initiation of the apoptosis in A2780/DDP cells. The results of this study indicate that polyMAG-l000 can be used as an efficient agent for TRAIL gene transfection in ovarian cancer cells. © 2011 Fang Li et al. Source

Discover hidden collaborations